| Document |
Document Title |
|
JP4320260B2 |
Arylamide derivatives (I) are new. Arylamide derivatives of formula (I) and their salts are new. [Image] X : optionally substituted lower alkylene or alkenylene; G 1O, S or NH; G 2C or N; R aH, halo or optionally substituted alkyl, cyclo...
|
|
JP2009528363A |
The invention includes a compound of formula I; wherein R 1 , X, Z, n, and m have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the a...
|
|
JP2009528278A |
This invention relates to the use of 5H-dibenz/b,f/azepine-5-carboxamide derivatives in the manufacture of various medicaments for treating neuropathic pain and for treating neurological disorders which involve both motor impairment and ...
|
|
JP2009527466A |
The present invention relates to crystalline forms of ECO-4601 and the processes for providing them. The invention further relates to pharmaceutical compositions comprising the crystalline forms and to methods of use of the crystalline f...
|
|
JPWO2007102392A1 |
If the activity of MMP-13 can be inhibited, it is considered that it greatly contributes to the improvement or prevention of progression of pathological conditions caused or related to the activity, especially osteoarthritis (OA). Develo...
|
|
JP4301953B2 |
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compo...
|
|
JP2009524702A |
Compounds of Formula I or pharmaceutically acceptable salts or solvates thereof: wherein Ar1, Ar2, A, X, Y, m, n and R1, R2, R3, R4 and R5 are as described in the specification, processes for their preparation, pharmaceutical formulation...
|
|
JP2009523150A |
The present invention relates to compounds of formula I wherein s, R1a and R1 to R3 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention...
|
|
JP2009522245A |
The present invention relates to dihydro-2,3-benzodiazepine compounds of high enantiomeric purity according to the general formula (I), which contain an asymmetric centre at the position 4 of the dihydro-2,3-benzodiazepine compound, and ...
|
|
JP4278008B2 |
The present invention relates to diamide derivatives represented by the following general formula (1): wherein A is a phenyl group or the like, which may be substituted, B is -CH=CH-, -C IDENTICAL C-, -(CH=CH)2-, -C IDENTICAL C-CH=CH-, -...
|
|
JP2009112319A |
To provide a method for identifying anti-HIV therapeutic compounds substituted with carboxyl ester or phosphonate ester groups.Libraries of such compounds are screened optionally using the novel enzyme GS-7340 Ester Hydrolase. Compositio...
|
|
JP2009519938A |
The present invention is directed to a process for the isolation of (R)-tofisopam with high enantiomeric purity and high overall yields from a mixture of tofisopam enantiomers by means of a non-steady state continuous chromatographic pro...
|
|
JP4265993B2 |
|
|
JP2009084291A |
To provide a new animal cell and its use.A diploid animal cell containing a mutation in at least one allele of the gene encoding the -isoenzyme of protein kinase C (PKC) gives lower PKC activity level than wild type-cells because of the ...
|
|
JP4250423B2 |
An aryl-substituted alicyclic compound of the formula (I): wherein U is 1,4,5,6-tetrahydropyrimidin-2-yl, etc., A is phenylene, etc., B is piperidine-1,4-diyl, etc., Z is -CONH-, etc., R<3> is hydrogen, etc., R<5> is hydrogen, aryl, etc....
|
|
JP2009513521A |
Methods for treatment of IP antagonist mediated diseases or conditions by administration to a subject in need thereof a compound of formula (I) wherein R1, R2, A and X are as defined herein. Also disclosed are compounds and related compo...
|
|
JP2009513644A |
The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and structurally and functionally related compoun...
|
|
JP4249610B2 |
Compounds of general formula (I): in which: R 1 is hydrogen, C 1 -C 20 alkyl, C 3 -C 10 cycloalkyl, C 4 -C 20 cycloalkylalkyl, aryl, arylalkyl, or two R 1 , taken together, form a straight or cyclic C 2 -C 10 alkylene group or an ortho d...
|
|
JP2009062329A |
To provide a new AGE formation inhibiting agent.The AGE formation inhibiting agent contains a homopiperazine derivative, its salt, or their solvates expressed by general formula (1) (wherein, R1, R2, R3, R4, R5 and R6 are each independen...
|
|
JP2009512730A |
Methods for treating and preventing anxiety, anxiety-related disorders, schizophrenia and schizophrenia-related disorders are described herein wherein said methods comprise the administration of oxytocin receptor agonists.
|
|
JP2009057281A |
To provide a P2X4 receptor antagonist.This P2X4 receptor antagonist uses a compound represented by general formula (I) (wherein, X is S or CH2; Y is O, S or NH; R1 is H, a 1-8C alkyl group, or the like; R2 and R3 are each H, a 1-8C alkyl...
|
|
JP2009509923A |
This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I) wherein A, B, D, E, X1, X2, X3, X4 and n are as defined in the specification.
|
|
JP2009051796A |
To provide a prophylactic-therapeutic agent strongly inhibiting differentiation from precursor adipocytes into adipocytes for diseases caused by an increase and hypertrophy of the adipocytes, e. g. obesity.N,N'-bis[5-(3,4,5-trimethoxyphe...
|
|
JP4238029B2 |
The present invention relates to compounds of the formula I, R<0>-Q-X-Q'-W-U-V-G-M in which Q; X; Q', U, V, G and M have the meanings indicated in the claims; R<0> is aryl or heteroaryl; and W is selected from aryl, heteroaryl, carbocycl...
|
|
JP4235103B2 |
A cyclic diamine compound of formula (1):wherein A is a single bond or C=C; X and Y are individually CH or a nitrogen atom; m is 1 or 2; and n is a number of 1 to 5; an acid-addition salt thereof, or a hydrate thereof. The compound has e...
|
|
JP2009507004A |
The present invention relates to the use of benzodiazepines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to benzo...
|
|
JP4225894B2 |
A cyclic diamine compound of formula (1): wherein R<1> and R<2> are individually a hydrogen atom or a methoxy group, provided R<1> is a methoxy group when R<2> is a hydrogen atom, or a hydrogen atom when R<2> is a methoxy group; A is an ...
|
|
JP2009504656A |
The present invention provides methods of treating and/or preventing pathologic cardiac hypertrophy and heart failure comprising administering hydroxamate compounds which are deacetylase inhibitors.
|
|
JP4219166B2 |
The invention relates to novel benzazepines and related heterocyclic derivatives (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes f...
|
|
JP2009503053A |
The invention relates to benzodiazepine derivatives having PDE2 inhibitory activities, as well as therapeutic methods by administering said compounds, in particular for treating various diseases of the central or peripheral nervous syste...
|
|
JP2009501176A |
Disclosed are pyridazine compounds of the formula I which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds:...
|
|
JP4205762B2 |
The present invention relates to novel classes of compounds which are inhibitors of interleukin-1² converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physiochemical features. This invent...
|
|
JP4204657B2 |
Medicaments comprising a compound represented by the following formulas: wherein, R<1> represents hydrogen atom or a C1-6 alkyl group; R<2> and R<3> represent hydrogen atom or a C1-6 alkyl group, or R<2> and R<3> may combine together wit...
|
|
JP4202438B2 |
Amidine derivs. of formula R3-NH-C(=NR1)-R-COR2 (I) and their salts are new. R = -Q-B-Q1-(CH2)n-, -Q-CH2-O-Phe-(CH2)p-, -Q-CH2-O-Phe-CH2-CH(NHR4)-, -Phe-NHCOCH2CH2CONHCHR5CH2-, -Phe-Q2(CH2)k-Q3-(CH2)l-, -Phe-CO-AA-Q4-OCH2-, -Phe-Phe-OCH2...
|
|
JP4201252B2 |
The invention refers to novel 2,3-benzodiazepine derivatives of formula (I) and pharmaceutical compositions containing the same as the active ingredient. The novel compounds antipasmodic, muscle relaxant and neuroprotective activities. I...
|
|
JP4200902B2 |
Glioblastoma remedies comprise an alpha-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid (AMPA) receptor antagonist. ACTIVITY : Cytostatic. In tests on nude mice implanted with CGNH-89 cells administration of [7-(1H-imidazol-1-yl)-6-n...
|
|
JP2008545757A |
The present invention relates to systems and methods for generating new forms of benzodiazepine and benzodiazepine related compounds as well as new compounds and formulations generated by such methods. In particular, the present inventio...
|
|
JP4189216B2 |
Compounds of formula Iwherein R is carboxy, esterified carboxy or amidated carboxy;R1 and R3 are independently lower alkyl, (hydroxy, lower alkoxy, amino, acylamino, mono- or di-lower alkylamino or mercapto)-lower alkyl, lower alkyl-(thi...
|
|
JP2008542308A |
The invention relates to pharmaceutical formulations comprising a farnesyl dibenzodiazepinone compound, or an analog, or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable surfactant and having impro...
|
|
JP2008285493A |
To provide a new kind of compounds and their pharmacologically acceptable derivatives useful as ICE inhibitors.The invention provides the new class of compounds which are ICE inhibitors represented by formulas of the figure, wherein vari...
|
|
JP4181291B2 |
A compound comprising a substituent of the formula (II) is disclosed as an HIV protease inhibitor. Intermediates for making such compounds and processes for making such intermediates are also disclosed.
|
|
JP2008538749A |
The present invention concerns novel compounds, their preparation and their uses, therapeutic uses in particular. More specifically it concerns derivative compounds having at least two aromatic cycles, their preparation and their uses, i...
|
|
JP4176148B2 |
Cyclic diamines of formula (I) or their pharmacologically acceptable acid addition salts, and their medical applications are described. These compounds inhibit the action of chemokines such as MIP-1a and/or MCP-1 on target cells, and are...
|
|
JP2008538357A |
The present invention provides 1.4- diazepam-2-ones of formula (I) wherein R1, R2 and R3 are as defined in the specification, which mediate LFA-1 activity; the use of such compounds for the treatment of conditions related to LFA-1 activi...
|
|
JP4166567B2 |
Compounds of formula IIA and IIB are novel guanidine compounds
Treatment of helper T cell-mediated immune disorders with retinoid antagonists
Retinoids with retinoid receptor antagonistic activity, pharmaceutically acceptable salts and pharmaceutically acceptable hydrolyzable esters thereof, have been found efficacious in treating T-helper cell type 2 (Th2)-mediated immune dis...
|
|
JP2008535790A |
Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorder...
|
|
JP4139453B2 |
|
|
JP4141499B2 |
The invention concerns compounds of formula (I), in which R1, R2, R3 and R4 mean hydrogen or different substituents; X means hydrogen or halogen; Y means C1-6 alkoxy or X and Y together mean -O-(CH2)n-O-; n means 1, 2 or 3; and A togethe...
|
|
JP2008533088A |
New N-hydroxyamides of n-alkyl carboxylic acids omega substituted with suitable tricyclic systems characterised by a central 7-membered ring, having activity as inhibitors of histone deacetylase (HDAC).
|
